Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Omeros May Be A Wonderful, Albeit Speculative, Biopharmaceutical Opportunity

Omeros May Be A Wonderful, Albeit Speculative, Biopharmaceutical Opportunity

Healthcare Sector and Stocks Analysis from Seeking Alpha

Wed, 6 Feb 2013

By Prescient Investment Analysis : Omeros ( OMER ) is a biopharmaceutical company that does not earn money and is financing itself through dilution and borrowing. There are plenty of things to like about the enterprise; however, the risks for investors are not easily overstated. Its products ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.